<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Press Coverage

Rivaroxaban reduces limb events after revascularization in patients with renal impairment

Default sub title

Author Healio | Publish Date August 16, 2021

In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced the primary composite endpoint, driven by a marked reduction in limb events, according to data from the VOYAGER PAD trial.